Meiou Dai, Ph.D.
Education : PhD in Experimental Medicine, University of McGill, Canada.
Current research : Genome-wide CRISPR/CAS9 loss-of-function screening for new cancer drug target discovery and biomarkers of drug resistance.
Ni Wang, Ph.D.
Jun Tian, Ph.D.
Education: Ph.D. in Experimental Medicine, McGill University
Current research: Investigation of the role of COX-2 and its associated genes in BCSC-mediated tumor metastasis and drug resistance.
Karine Pasturaud, Ph.D.
Mostafa Ghozlan, Ph.D. candidate
Sophie Poulet, Ph.D. Candidate
Julien Boudreault, Ph.D. Candidate
Education : M.Sc. in Molecular Biology at the University of Sherbrooke.
Current Research : The production of genetically modified cancer cell lines using the CRISPR technology and the cytotoxic study of kinase inhibitors in breast cancer.
Gang Yan, Ph.D. candidate
Education : B.Sc. in Biochemistry and Molecular Biology, Northeast Agricultural University, China.
Current research : Utilizing genome-wide Crispr/Cas9 screen based on paclitaxel to identify key genetic mutations responsible for paclitaxel resistance in triple negative breast cancer.
Education : Graduate degree in experimental surgery, McGill university, Montreal, Canada
High diploma in medical laboratories, High institute of medical technology, El-beyda, Libya.
Current research : TGF-beta1 mutation project, assessment of the effect of TGF-beta1 in the intensified bone formation and muscles disorder growth, translating current clinical data with the fundamental science in order to highlight its rule in a comprehensive manner, and deliver new therapeutic avenue.
Education : Diploma in Biotechnology, Algonquin College, Canada
Education : MSc in Molecular Pathology and Toxicology, Leicester University, UK
Program Assistant, Cancer Research Program (CRP)